drugset
drugset / Trial / NCT02446132

Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

NCT02446132 ↗

Phase 3 Terminated 1197 enrolled Otsuka Pharmaceutical Development & Commercialization, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This was an extension study of the Phase 3 Studies 15-AVP-786-301, 15-AVP-786-302, and 17-AVP-786-305.

Timeline

Start
2015-11-13
Primary completion
2024-09-06
Completion
2024-09-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Deudextromethorphan Unknown 18 mg Oral
Subject Deudextromethorphan Unknown 28 mg Oral
Subject Deudextromethorphan Unknown 42.63 mg Oral
Background Quinidine Small molecule 4.9 mg Oral

Indications

No indication recorded.